NEW YORK, March 07, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on PRTK, PDLI, PGNX, and PRTA which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com takes a close look at the recent performance of Paratek Pharmaceuticals
On Tuesday, shares in Boston, Massachusetts headquartered Paratek Pharmaceuticals Inc. recorded a trading volume of 318,562 shares. The stock ended flat at $13.70. The Company's shares are trading below their 50-day moving average by 12.72%. Furthermore, shares of Paratek Pharma, which focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the US, have a Relative Strength Index (RSI) of 42.66.
On March 02nd, 2018, research firm Raymond James downgraded the Company's stock rating from 'Strong Buy' to 'Outperform'.
On March 02nd, 2018, Paratek Pharma announced that its President, COO, and Chief Medical Officer, Evan Loh, MD, will present at the upcoming 38th Annual Cowen & Co. Health Care Conference on March 12th, 2018, at 11:20 a.m. ET at the Boston Marriott Copley Place in Boston. Get the full research report on PRTK for free by clicking below at: www.wallstequities.com/registration/?symbol=PRTK
Incline Village, Nevada headquartered PDL BioPharma Inc.'s stock finished yesterday's session 4.13% higher at $2.52. A total volume of 1.37 million shares was traded, which was above their three months average volume of 1.35 million shares. The Company's shares have gained 18.31% over the past year. The stock is trading below its 50-day moving average by 6.49%. Furthermore, shares of PDL BioPharma, which acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the US, Europe, and internationally, have an RSI of 47.67.
On February 26th, 2018, LENSAR, Inc., a wholly owned subsidiary of PDL BioPharma, announced that world-renowned ophthalmologist Richard L. Lindstrom, M.D. has joined the Company's board of directors, effective immediately. Dr. Lindstrom, founder and attending surgeon of Minnesota Eye Consultants and Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology, is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive, and laser surgery. The free technical report on PDLI can be accessed at: www.wallstequities.com/registration/?symbol=PDLI
At the close of trading on Tuesday, shares in New York-based Progenics Pharmaceuticals Inc. climbed 1.27%, ending the day at $7.17. The stock recorded a trading volume of 975,165 shares. The Company's shares have advanced 32.53% in the last month and 26.23% in the previous three months. The stock is trading 17.65% and 13.76% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have an RSI of 72.72.
On March 01st, 2018, Progenics Pharma announced that it will host a conference call and webcast on March 08th, 2018, at 8:30 a.m. ET to review its financial results for the fourth quarter and year ended December 31st, 2017. A live webcast will be available under the Media Center section of the Company's website. Sign up for free on Wall St. Equities and claim the latest report on PGNX at: www.wallstequities.com/registration/?symbol=PGNX
Dun Laoghaire, Ireland headquartered Prothena Corp. PLC's shares ended the day 0.56% higher at $34.03 with a total trading volume of 338,352 shares. The stock is trading 7.23% below its 50-day moving average. Shares of the Company, which focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories, have an RSI of 48.44.
On February 14th, 2018, Prothena reported its financial results for Q4 2017 and full year 2017. For Q4 2017, net loss was $(47.8) million, and total revenue was $0.2 million. For the full year 2017, net loss was $(153.2) million, and total revenue was $27.5 million. As of December 31st, 2017, the Company had $421.7 million in cash, cash equivalents and restricted cash, and no debt. See the free research coverage on PRTA at: www.wallstequities.com/registration/?symbol=PRTA
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-biotech-stocks----paratek-pharma-pdl-biopharma-progenics-pharma-and-prothena-300609744.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All